LSD helps to treat alcoholism Retrospective analysis shows hallucinogenic drug helped problem drinkers. Arran Frood Nature, 09 March 2012 doi : 10.1038/nature.2012.10200 Rights & Permissions DEA/Science Faction/Corbis An analysis of old studies suggests LSD may have a role to play in treating alcoholism. The powerful hallucinogen LSD (lysergic acid diethylamide) has potential as a treatment for alcoholism, according to a retrospective analysis of studies published in the late 1960s and early 1970s. The study1, by neuroscientist Teri Krebs and clinical psychologist Pål-Ørjan Johansen of the Norwegian University of Science and Technology in Trondheim, is the first-ever quantitative meta-analysis of LSD–alcoholism clinical trials. The researchers sifted through [...]
Lire la suiteLSD : le retour de l’enfant terrible par Didier ACIER pour laviedesidees.fr, https://laviedesidees.fr/LSD-le-retour-de-l-enfant-terrible.html 6 mars 2015 Indissociable du mouvement hippie, l’usage récréatif de LSD-25 a donné lieu à l’interdiction précoce de ce médicament. Le potentiel psychothérapeutique de l’acide lysergique diéthylamide est pourtant bien établi, notamment en matière de soins palliatifs, et l’on peut souhaiter que l’exploration scientifique et médicale de ce produit se développe à l’avenir. Genèse d’un médicament Printemps 1943 en Suisse, à Bâle. Albert Hoffmann, chimiste de son état, synthétise pour la compagnie Sandoz, des alcaloïdes, à partir de l’ergot de seigle. Sa recherche vise à développer de nouveaux médicaments. Alors qu’il travaille sur l’acide [...]
Lire la suiteA Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy Ben Sessa, Laurie Higbed and David Nutt Frontiers in Psychiatry, 2019, Vol. 10, article 138 DOI : 10.3389/fpsyt.2019.00138 Neuropsychopharmacology Unit, Department of Medicine, Imperial College London, London, United Kingdom Abstract : This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA therapy are described, including contemporary studies treating anxiety associated with autism and the authors’ ongoing study exploring the potential [...]
Lire la suiteClinical Interpretations of Patients Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder BOGENSCHUTZ M.P., PODREBARAC S.K., DUANE J.H., AMEGADZIE S.S., MALONE T.C., ROSS L.T., MENNENGA S.E. Frontiers in Pharmacology, 2018, 9, article 100. Doi : 10.3389/fphar.2018.00100 Abstract : After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete, descriptive case studies provide a useful window into the therapeutic process [...]
Lire la suiteThe neurobiology of addiction George R. Uhl, George F. Koob, and Jennifer Cable ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2019 Special Issue: Addiction Reviews https://doi.org/10.1111/nyas.13989 Substance and alcohol use disorders impose large health and economic burdens on individuals, families, communities, and society. Neither prevention nor treatment efforts are effective in all individuals. Results are often modest. Advances in neuroscience and addiction research have helped to describe the neurobiological changes that occur when a person transitions from recreational substance use to a substance use disorder or addiction. Understanding both the drivers and consequences of substance use in vulnerable populations, including those whose brains are [...]
Lire la suite